ResMed's CEO Discusses CEO Discusses F2Q2012 Results - Earnings Call Transcript

ResMed Inc. ( RMD)

F2Q2012 (Qtr End 12/31/2011) Earnings Call

January 26, 2012 04:30 pm ET


Peter Farrell - Founder, Chairman, and CEO

Brett Sandercock - CFO

Rob Douglas - COO

Don Darkin - President, SDB Strategic Business Unit

Geoff Neilson - President, Respiratory Care Strategic Business Unit

Mick Farrell – President, Americas


Ben Andrew - William Blair

Michael Matson - Mizuho Securities

Joanne Wuensch - BMO Capital Markets

Jason Mills - Canaccord

Matthew Prior - Bank of America Merrill Lynch

David Clair - Piper Jaffray

Dan Hurren - UBS

David Low - Deutsche Bank



Good day ladies and gentlemen and welcome to the second quarter 2012 ResMed Inc earnings conference call. My name is Stacy and I will be your conference moderator for today. At this time all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of the conference. (Operator Instructions) As a reminder, this conference call is being recorded for replay purposes.

In addition the company asks me to address certain matters. First, ResMed does not authorize the recording of any portion of this conference call for any purpose. Second, during the conference call, ResMed may make forward-looking statements such as projections of future revenue or earnings, new product development or new markets of the company’s products. These statements are made under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995.

Risks and uncertainties exist that could cause actual results to materially differ from the forward-looking statements. These factors are discussed in ResMed’s SEC filings such as Forms 10-Q and 10-K, which you may access through the company’s website at

If you liked this article you might like

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

ResMed: Cramer's Top Takeaways

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why a Massive Short Squeeze Could Send These 4 Stocks Into Orbit

ResMed (RMD) Stock Sharply Lower After Q1 Results Miss Estimates